Answering the Call: Nurse-Led Strategies to Improve Compliance with Hemophilia Prophylaxis

Released On
December 27, 2021

Expires On
December 27, 2022

Media Type

Completion Time
60 minutes

Hematology-Oncology, Pediatrics

Bleeding Disorders, Hemophilia, Pediatrics

Scroll to the Bottom of this Information to Begin this Course

This activity is sponsored by the Academy for Continued Healthcare Learning (ACHL) and Purdue University College of Pharmacy.

This activity is supported by an educational grant from Sanofi Genzyme.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 contact hours.

The American Association of Nures Practitioner and American Academy of Physician Assistants accept edcuational activities certified from AMA PRA Category 1 Credit

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This educational activity is designed for advanced practice nurses (APRN) including nurses and nurse practitioners (NP), physicians, and other clinicians in a hematology setting treating patients with hemophilia A

Program Overview

Prophylactic management of hemophilia continues to be a challenge. The nurse-led activity discusses treatment strategies, safety and efficacy of current available products, and how to improve patient adherence. In this clinical commentary, expert faculty, Kerry H. Hansen, RN, BS and Skye Peltier, MPH,
PA-C review best practices to facilitate successful therapeutic interventions with hemophilia A prophylaxis.

Activity Purpose

Nurses’ and nurse practitioners’ training and function in the healthcare environment is unique from that of physicians and other healthcare professionals. Therefore, they require specialized continuing education programming that is applicable to their specific practice, serves to strengthen their clinical knowledge base, and gives them skills that they can apply in daily practice related to hemophilia A care. An innovative CE strategy targeting nurses and APRNs is an ideal way to support these clinicians in gaining knowledge that can be applied in everyday practice. This in turn, allows nurses and APRNs to provide the best care and optimize outcomes for people with hemophilia A.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe strategies for developing an individualized plan for hemophilia A prophylaxis
  • Demonstrate knowledge of extended half-life and non-factor products for hemophilia A prophylaxis
  • Explain strategies to improve and reinforce adherence in patients prescribed hemophilia A prophylaxis




Kerry H. Hansen, RN, BS

Fairview Center for Bleeding and Clotting Disorders
Minneapolis, MN


Skye Peltier, MPH, PA-C

Fairview Center for Bleeding and Clotting Disorders
Minneapolis, MN


Special thanks to Enrique Tapia (patient) who shared his hemophilia A journey and perspective

Accreditation Statement

Purdue University College of Pharmacy is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Credit Designation

Purdue University College of Pharmacy designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Purdue University Continuing Nursing Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This program is approved for 1.0 contact hours

Disclosures of Conflicts of Interest

Purdue University College of Pharmacy requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Kerry H. Hansen, RN, BS
Advisory Board Membership: Novo Nordisk

Skye Peltier, MPH, PA-C
Speakers Bureau: Novo Nordisk
Advisory Board Membership: Novo Nordisk, Sanofi Genzyme

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

Staff Disclosures

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Instructions for Participation and Credit

This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.


The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, as well as the ACPE Accreditation Standards for Continuing Pharmacy Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information

For questions, contact Karen Catino at